

A randomised comparison of ten versus three fractions of radiotherapy for palliation in patients unsuitable for radical radiotherapy or chemotherapy

Submission date 28/02/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 28/02/2001	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 11/09/2007	Condition category Cancer	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Barbara Uscinska

Contact details

MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

BA09

Study information

Scientific Title

Study objectives

To compare the efficacy and side effects of two palliative radiotherapy schedules in patients with bladder cancer considered unsuitable for radical radiotherapy or chemotherapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cancer

Interventions

Two palliative radiotherapy schedules in patients with bladder cancer considered unsuitable for radical radiotherapy or chemotherapy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Change in bladder and bowel symptoms at three months, quality of life, response, survival.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/11/1992

Completion date

01/11/1997

Eligibility

Key inclusion criteria

Life expectancy of at least three months, no planned administration of cytotoxic chemotherapy

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

500

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/11/1992

Date of final enrolment

01/11/1997

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results:	01/05/2000		Yes	No